These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 21270185)
1. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Saito Y; Morimoto T; Ogawa H; Nakayama M; Uemura S; Doi N; Jinnouchi H; Waki M; Soejima H; Sugiyama S; Okada S; Akai Y; Diabetes Care; 2011 Feb; 34(2):280-5. PubMed ID: 21270185 [TBL] [Abstract][Full Text] [Related]
2. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. Ogawa H; Nakayama M; Morimoto T; Uemura S; Kanauchi M; Doi N; Jinnouchi H; Sugiyama S; Saito Y; JAMA; 2008 Nov; 300(18):2134-41. PubMed ID: 18997198 [TBL] [Abstract][Full Text] [Related]
3. Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial. Okada S; Morimoto T; Ogawa H; Kanauchi M; Nakayama M; Uemura S; Doi N; Jinnouchi H; Waki M; Soejima H; Sakuma M; Saito Y; Diabetes Care; 2011 Jun; 34(6):1277-83. PubMed ID: 21515838 [TBL] [Abstract][Full Text] [Related]
4. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Soejima H; Ogawa H; Morimoto T; Nakayama M; Okada S; Uemura S; Kanauchi M; Doi N; Sakuma M; Jinnouchi H; Sugiyama S; Waki M; Saito Y; Circ J; 2012; 76(6):1526-32. PubMed ID: 22447019 [TBL] [Abstract][Full Text] [Related]
5. Is Long-Term Low-Dose Aspirin Therapy Associated with Renal Dysfunction in Patients with Type 2 Diabetes? JPAD2 Cohort Study. Okada S; Morimoto T; Ogawa H; Sakuma M; Soejima H; Nakayama M; Jinnouchi H; Waki M; Akai Y; Ishii H; Saito Y; PLoS One; 2016; 11(1):e0147635. PubMed ID: 26808136 [TBL] [Abstract][Full Text] [Related]
6. Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: subanalysis from the JPAD trial. Soejima H; Ogawa H; Morimoto T; Nakayama M; Okada S; Sakuma M; Uemura S; Kanauchi M; Doi N; Jinnouchi H; Sugiyama S; Waki M; Saito Y; J Cardiol; 2013 Sep; 62(3):165-70. PubMed ID: 23778008 [TBL] [Abstract][Full Text] [Related]
7. One quarter of total myocardial infarctions are silent manifestation in patients with type 2 diabetes mellitus. Soejima H; Ogawa H; Morimoto T; Okada S; Sakuma M; Nakayama M; Masuda I; Doi N; Uemura S; Jinnouchi H; Sugiyama S; Waki M; Saito Y; J Cardiol; 2019 Jan; 73(1):33-37. PubMed ID: 30487058 [TBL] [Abstract][Full Text] [Related]
8. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325 [TBL] [Abstract][Full Text] [Related]
9. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial. Saito Y; Okada S; Ogawa H; Soejima H; Sakuma M; Nakayama M; Doi N; Jinnouchi H; Waki M; Masuda I; Morimoto T; Circulation; 2017 Feb; 135(7):659-670. PubMed ID: 27881565 [TBL] [Abstract][Full Text] [Related]
10. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial. Tanaka A; Shimabukuro M; Okada Y; Sugimoto K; Kurozumi A; Torimoto K; Hirai H; Node K; Cardiovasc Diabetol; 2020 Jun; 19(1):85. PubMed ID: 32534578 [TBL] [Abstract][Full Text] [Related]
11. Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial. Matsumoto C; Ogawa H; Saito Y; Okada S; Soejima H; Sakuma M; Masuda I; Nakayama M; Doi N; Jinnouchi H; Waki M; Morimoto T; ; Diabetes Care; 2020 Feb; 43(2):314-320. PubMed ID: 31801787 [TBL] [Abstract][Full Text] [Related]
12. [Investigation of the effects of low dose aspirin therapy on primary and secondary prevention of cardiovascular disease]. Soejima H; Ogawa H Nihon Rinsho; 2010 May; 68(5):882-6. PubMed ID: 20446587 [TBL] [Abstract][Full Text] [Related]
13. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Udell JA; Bhatt DL; Braunwald E; Cavender MA; Mosenzon O; Steg PG; Davidson JA; Nicolau JC; Corbalan R; Hirshberg B; Frederich R; Im K; Umez-Eronini AA; He P; McGuire DK; Leiter LA; Raz I; Scirica BM; Diabetes Care; 2015 Apr; 38(4):696-705. PubMed ID: 25552421 [TBL] [Abstract][Full Text] [Related]
14. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). Goicoechea M; de Vinuesa SG; Quiroga B; Verde E; Bernis C; Morales E; Fernández-Juárez G; de Sequera P; Verdalles U; Delgado R; Torres A; Arroyo D; Abad S; Ortiz A; Luño J Cardiovasc Drugs Ther; 2018 Jun; 32(3):255-263. PubMed ID: 29943364 [TBL] [Abstract][Full Text] [Related]
15. The prognosis of subjects showing a reduced estimated glomerular filtration rate without albuminuria in Japanese patients with type 2 diabetes: a cohort study for diabetic kidney disease. Ito H; Antoku S; Izutsu T; Kusano E; Matsumoto S; Yamasaki T; Mori T; Togane M Clin Exp Nephrol; 2020 Nov; 24(11):1033-1043. PubMed ID: 32734506 [TBL] [Abstract][Full Text] [Related]
16. Relationship between peripheral artery disease and combined albuminuria and low estimated glomerular filtration rate among elderly patients with type 2 diabetes mellitus. Yap YS; Chuang HY; Chien CM; Tai YK Diab Vasc Dis Res; 2014 Jan; 11(1):41-7. PubMed ID: 24227538 [TBL] [Abstract][Full Text] [Related]
17. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815 [TBL] [Abstract][Full Text] [Related]
18. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G; J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588 [TBL] [Abstract][Full Text] [Related]
19. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial). Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260 [TBL] [Abstract][Full Text] [Related]
20. Urinary Potassium Excretion and Renal and Cardiovascular Complications in Patients with Type 2 Diabetes and Normal Renal Function. Araki S; Haneda M; Koya D; Kondo K; Tanaka S; Arima H; Kume S; Nakazawa J; Chin-Kanasaki M; Ugi S; Kawai H; Araki H; Uzu T; Maegawa H Clin J Am Soc Nephrol; 2015 Dec; 10(12):2152-8. PubMed ID: 26563378 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]